Zepbound Beats Wegovy For Weight Loss In First Head-To-Head Trial Of Blockbuster Drugs

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold ...Read more